logo

LLY

Eli Lilly·NYSE
--
--(--)
--
--(--)
5.16 / 10
Netural

Fundamental evaluation presents moderate characteristics (5.2/10). Strengths encompass Days sales outstanding and Cost of sales ratio (%), while concerns exist in PB-ROE and Revenue-MV. This justifies cautious view.

Fundamental(5.16)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.80
Score1/3
Weight9.74%
1M Return4.20%
Days sales outstanding
Value60.79
Score3/3
Weight2.45%
1M Return1.30%
Profit-MV
Value0.36
Score2/3
Weight21.99%
1M Return9.19%
PB-ROE
Value5.25
Score0/3
Weight4.84%
1M Return2.29%
Income tax / Total profit (%)
Value19.79
Score2/3
Weight4.61%
1M Return2.06%
Interest coverage ratio (EBIT / Interest expense) (%)
Value41.08
Score2/3
Weight-1.18%
1M Return-0.66%
Operating revenue (YoY growth rate %)
Value44.70
Score2/3
Weight1.02%
1M Return0.55%
Cost of sales ratio (%)
Value16.96
Score3/3
Weight1.44%
1M Return0.72%
Asset-MV
Value-0.50
Score3/3
Weight32.23%
1M Return12.82%
Cash-MV
Value0.07
Score3/3
Weight22.86%
1M Return9.70%
Is LLY undervalued or overvalued?
  • LLY scores 5.16/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 31.67% net margin, 48.47 P/E ratio, 41.94 P/B ratio, and 95.42% earnings growth, these metrics solidify its Netural investment rating.